1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Filana Therapeutics, Inc.

Filana Therapeutics, Inc.

FLNA
Filana Therapeutics, Inc.US flagNASDAQ Global Market
0.97
USD
-0.04
- -
46.86MMarket Cap
Filana Therapeutics, Inc.
FLNA
(NASDAQ Global Market)

Recent

price

0.97

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2.76
1.82
1.7
6.4
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-1.97
-0.41
-0.54
4.91
-1.92
-2.16
-2.28
-1.82
-0.61
-0.27
-0.24
-0.82
-1.9
-2.32
-0.53
-1.88
-1.61
Basic EPS, GAAP
-0.02
-0.04
-1.12
-1.08
-1.49
-1.41
-1.89
-1.26
-0.45
-0.15
-0.21
-1.33
-2
-1.97
-2.53
-0.68
-0.63
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-21.27
-20.95
-21.21
-16.18
-18.01
-19.98
-22.31
-24.08
-15.35
-9.68
-6.7
-5.26
-7.05
-9.08
-8.74
-10.27
-10.48
Book Value per Share
5.41
7.04
2.05
7.51
6.19
4.49
2.86
1.48
1.84
1.27
3.53
6.42
5.64
3.27
3.14
1.54
1.41
Tangible Book Value per Share
6
6
6
6
6
7
7
7
11
17
26
39
40
42
46
48
48
Basic Weighted Avg Shares
17
11
11
41
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-81.52
-30.6
-35.79
76.28
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
2
1
1
1
Depreciation Expense
-12
-3
-3
32
-12
-14
-15
-12
-7
-5
-6
-32
-76
-97
-24
-91
-78
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-71.53
-22.75
-31.64
76.71
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
84
85
47
48
40
29
18
10
20
22
92
232
204
115
125
54
48
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
33
44
13
48
40
29
19
10
20
22
92
254
228
137
146
74
68
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
48
48
48
Market Capitalization
- -
- -
82

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
109
98
88
Cash, Cash Equivalents & STI
106
96
87
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
48
44
40
Payables & Accruals
47
42
40
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
43.02%
16.5%
-48.94%
Free Cash Flow
92.32%
179.93%
-71.95%
Net Income, GAAP
72.06%
154.6%
273.73%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.58
0.13
-0.58
-0.57
-0.53
2025
-0.48
-0.92
-0.22
-0.26
-1.88
2026
-0.21
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
BriaCell Therapeutics Corp. (BCTXW)
Entropy Neurodynamics Limited (ENP.AX)
Immutep Ltd (PRRUF)
OncoZenge AB (publ) (ONCOZ.ST)
Clinuvel Pharmaceuticals Limited (CLVLY)
RespireRx Pharmaceuticals Inc. (RSPI)
Business
Filana Therapeutics, Inc. is a clinical‑stage biotechnology company focused on developing novel medicines to modulate the filamin A protein for the treatment of central nervous system disorders, including tuberous sclerosis complex (TSC)–related epilepsy, and other diseases associated with filamin A dysregulation. The company aims to address unmet medical needs by advancing its lead candidate simufilam, a proprietary small molecule oral therapy, through late‑stage development; it is also pursuing diagnostic and biomarker programs such as SavaDx to detect Alzheimer's disease. Filana Therapeutics operates from its headquarters in Austin, Texas, and has ongoing research and development collaborations and clinical activities aimed at expanding its portfolio and validating filamin A–targeted approaches across CNS indications. Founded in 1998, the company previously operated under a different corporate name and branding and recently rebranded to reflect its strategic emphasis on filamin A–related therapeutics and CNS disease modulation. Filana Therapeutics’ product and service scope includes: development of small molecule therapies targeting filamin A; clinical trial management and execution; biomarker and diagnostic asset development; strategic partnerships and collaborations for drug development, regulatory submission support, and translational research; and ongoing monitoring of regulatory interactions, including responses to agency inquiries, to advance its clinical programs and optimize capital efficiency. The company’s geographic footprint centers on the United States with R&D activities and trials conducted via affiliated sites and collaborations, supported by a network of scientific and clinical advisors and partner organizations to advance its CNS disorder pipeline. Filana Therapeutics’ business segments span therapeutic development, diagnostic asset exploration, and corporate partnerships, with a primary emphasis on CNS diseases tied to filamin A biology.

Company News

APIChatGPT

  • globenewswire.com

    Filana Therapeutics Reports Q1 2026 Financial Results and Business Update

  • globenewswire.com

    Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII

  • defenseworld.net

    Zevra Therapeutics (NASDAQ:ZVRA) versus Cassava Sciences (NASDAQ:FLNA) Head-To-Head Contrast